Head and Neck Carcinoma Clinical Trial
Official title:
The Effect of Exercise Prehabilitation on Post-Operative Recovery After Head and Neck Cancer Surgery
Verified date | May 2024 |
Source | OHSU Knight Cancer Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This clinical trial evaluates a prehabilitation exercise intervention for improving mobility and recovery outcomes in patients undergoing surgery for head and neck cancer. Prehabilitation focuses on optimizing health before surgery in order to improve outcomes after surgery. Prehabilitation may include aspects of nutrition, exercise, mental health, or a combination of these. Exercise has been proven to improve anxiety, depression, fatigue, health related quality of life, and physical function among patients undergoing cancer treatment, as well as cancer survivors. The prehabilitation exercise intervention being studied includes a daily walking program, sit-to-stand training, and standing therapeutic exercises before patients undergo surgery. Receiving this prehabilitation exercise intervention prior to surgery may improve mobility and recovery outcomes in patients after surgery for head and neck cancer.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | October 31, 2024 |
Est. primary completion date | October 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 89 Years |
Eligibility | Inclusion Criteria: - Older than 18 years of age and younger than 89 years of age. Both men and women and members of all races and ethnic groups may be included - Planned to undergo major head and neck cancer surgery with free tissue transfer reconstruction at Oregon Health and Science University (OHSU) with the Department of Otolaryngology-Head and Neck Surgery with an expected length of stay (LOS) of 3 days or more - Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: - Non-English speaking - Planned postoperative admission to the intensive care unit (ICU) - Social or psychiatric conditions that may interfere with compliance - Further exclusion criteria may be applied due to conditions that may impact the ability to safely exercise as well as utilize the Fitbit devices: - Symptoms of or ongoing work-up for unstable angina, uncontrolled tachyarrhythmias, decompensated heart failure, severe aortic stenosis, hypertrophic obstructive cardiomyopathy, uncontrolled hypertension (HTN), uncontrolled pulmonary HTN or uncontrolled asthma - History of chest pain, dizziness or syncope with exercise - Bony metastases to the spine or extremities - Falls in the last year - Cognitive impairments limiting safety or ability to use technology - Impaired mobility requiring the use of assistive devices, such as use of a walker or wheelchair at baseline - Isolation precautions, as they would not be allowed to ambulate on a patient floor post-operatively |
Country | Name | City | State |
---|---|---|---|
United States | OHSU Knight Cancer Institute | Portland | Oregon |
Lead Sponsor | Collaborator |
---|---|
OHSU Knight Cancer Institute |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Post-operative mobility | Will be measured by daily step counts on the Fitbit or personal wearable device. Descriptive summaries of continuous data will include the sample size, group mean, standard deviation, median, and range. Confidence intervals will be included as appropriate. The primary endpoint of daily post-operative step counts will be compared using two sample t-tests between the intervention and control groups. | Up to day of discharge or 14 days post-operatively, whichever is sooner. | |
Secondary | Post-operative complications | Will be derived from the medical chart, and include pneumonia, DVT, ileus, arrhythmia, wound infection and any events requiring ICU transfer. Descriptive statistics will be used to present the results. A two-sample t-test will be used to analyze continuous variables and Chi-square test will be used for categorical variables. | Up to day of discharge or 14 days post-operatively, whichever is sooner. | |
Secondary | Length of stay | Derived from the medical record. Descriptive statistics will be used to present the results. A two-sample t-test will be used to analyze continuous variables and Chi-square test will be used for categorical variables. | From post-operative day 1 until day of discharge or 14 days post-operatively, whichever is sooner. | |
Secondary | Depression | Measured with the Patient Health Questionnaire-9 (PHQ-9) to determine level of depression on the day of discharge. This screening instrument measures the frequency of 9 signs and symptoms diagnostic of depression, with answers as not at all, several days, more than half of the days, and nearly every day. Total scores range between 0-27, and can indicate mild (<4), moderate (5-14), or severe (>20) depression. Descriptive statistics will be used to present the results. A two-sample t-test will be used to analyze continuous variables and Chi-square test will be used for categorical variables. | Up to day of discharge or 14 days post-operatively, whichever is sooner. | |
Secondary | Health-related quality of life | Measured with the European Organization of Research and Treatment of Cancer Quality of Life Core Questionnaire, version 3.0 (EORTC QLQ C30). A 30-item questionnaire to assess overall quality of life in cancer patients. EORTC QLQ-C30 includes functional scales (physical, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and other (dyspnea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties). Most questions use 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions use 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged and transformed to 0-100 scale; higher score equates to better level of physical functioning. Descriptive statistics will be used to present the results. A two-sample t-test will be used to analyze continuous variables and Chi-square test will be used for categorical variables. | Up to day of discharge or 14 days post-operatively, whichever is sooner. | |
Secondary | Weight loss | Measured in kg. Weight loss will be determined based on their weight at the time of enrollment at initial pre-operative appointment, compared to their weight on the day of discharge. Descriptive statistics will be used to present the results. A two-sample t-test will be used to analyze continuous variables and Chi-square test will be used for categorical variables. | From time of enrollment to day of discharge or 14 days post-operatively, whichever is sooner. | |
Secondary | Average daily pain scores | Measured on a 1-10 Likert scale, during a patient's inpatient, post-operative stay and obtained from the medical record. Descriptive statistics will be used to present the results. A two-sample t-test will be used to analyze continuous variables and Chi-square test will be used for categorical variables. | Up to day of discharge or 14 days post-operatively, whichever is sooner. | |
Secondary | Discharge Disposition | Derived from the medical record and may include discharge to home, home with assistance, home with home health, skilled nursing facility, inpatient rehabilitation facility or other facility. Descriptive statistics will be used to present the results. A two-sample t-test will be used to analyze continuous variables and Chi-square test will be used for categorical variables. | At time of discharge or 14 days post-operatively, whichever is sooner. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04110249 -
Photoacoustic Imaging for Measuring Tumors and Normal Tissue in Patients With Head and Neck Cancer
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Completed |
NCT01831089 -
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT03663985 -
FALCOn (Facteur AnthropoLogique Cancer Orl)
|
||
Recruiting |
NCT05544136 -
A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer
|
Phase 2 | |
Recruiting |
NCT05077072 -
Interdisciplinary Interventions to Address Pain Management Among Head and Neck Cancer Patients
|
Phase 2 | |
Recruiting |
NCT04151082 -
High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors
|
Phase 1/Phase 2 | |
Completed |
NCT03964896 -
Nurse-Driven Telephone Intervention in Improving Side Effects in Cancer Patients Undergoing Chemotherapy
|
N/A | |
Recruiting |
NCT04147494 -
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
|
Early Phase 1 | |
Completed |
NCT02474095 -
Acupuncture-Like Transcutaneous Electrical Nerve Stimulation in Treating Radiation-Induced Xerostomia in Patients With Head and Neck Cancer
|
N/A | |
Withdrawn |
NCT03261180 -
Nestle Impact Advanced Recovery in Improving Surgery Recovery in Patients With Head and Neck Cancer
|
N/A | |
Terminated |
NCT04618432 -
Collection of Clinical Data and Specimens for Research on Head and Neck and Communication Disorders
|
||
Active, not recruiting |
NCT02615275 -
Bioelectrical Impedance Analysis in Estimating Body Composition in Patients With Stage I-IV Head and Neck Cancer Undergoing Radiation Therapy
|
N/A | |
Terminated |
NCT05012397 -
Milademetan in Advanced/Metastatic Solid Tumors
|
Phase 2 | |
Recruiting |
NCT00991094 -
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
|
||
Recruiting |
NCT04870762 -
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
|
Phase 2 | |
Completed |
NCT02369835 -
Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
|
Phase 3 | |
Completed |
NCT03902535 -
Geriatric and Quality of Life Assessments in Older Patients With Non-metastatic or Metastatic Head and Neck or Lung Cancer Undergoing Surgery or Chemoradiation and Their Caregivers
|
||
Recruiting |
NCT05526924 -
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
|
Phase 1 | |
Recruiting |
NCT03795610 -
Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma
|
Phase 2 |